3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
15
Neoplasms
8
cyclopia sequence
7
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Fatigue
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain
3
Obesity
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Leiomyoma
3
Vomiting
2
Urinary Bladder Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms, Plasma Cell
2
Nausea
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Insulin Resistance
2
Infertility
2
Hyperandrogenism
2
Hematologic Diseases
2
Depression
2
Burkitt Lymphoma
2
Weight Loss
1
Interventions
Sirolimus
9
Everolimus
5
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphangioleiomyomatosis
×
Sugars
×
Clear all
NCT01353209
2024-04-17
TRAIL
University of Cincinnati
Phase 2
Completed
17 enrolled
13 charts